'Valsartan' presentation slideshows

Valsartan - PowerPoint PPT Presentation

Acute Heart Failure Chief Rounds, Sept. 14, 2009 Dr. Frederic L. Ginsberg

Acute Heart Failure Chief Rounds, Sept. 14, 2009 Dr. Frederic L. Ginsberg

Acute Heart Failure Chief Rounds, Sept. 14, 2009 Dr. Frederic L. Ginsberg. CJTMEustaquio, MD PGY-3. Internal Medicine Cooper University Hospital. I. Introduction - Definition & Causes - General Approach II. Case 1: LS, 62M. cc: chest pain - Discussion: Management

★ ★ ★ ★ ★

624 views • 49 slides
Toyoaki Murohara, Takashi Muramatsu , Kunihiro Matsushita ,

Toyoaki Murohara, Takashi Muramatsu , Kunihiro Matsushita ,

Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Toyoaki Murohara, Takashi Muramatsu , Kunihiro Matsushita ,

★ ★ ★ ★ ★

471 views • 30 slides
Heart Failure Management

Heart Failure Management

Heart Failure Management. Focus on Primary Care Practice. mgray@medsfgh.ucsf.edu. Framingham Clinical Diagnostic Criteria Patients considered to have validated CHF if two major criteria or one major and two minor criteria were present concurrently. Major Criteria:

★ ★ ★ ★ ★

498 views • 30 slides
Toyoaki Murohara, Takashi Muramatsu , Kunihiro Matsushita ,

Toyoaki Murohara, Takashi Muramatsu , Kunihiro Matsushita ,

Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Toyoaki Murohara, Takashi Muramatsu , Kunihiro Matsushita ,

★ ★ ★ ★ ★

517 views • 30 slides
Study Results

Study Results

Study Results. Background: experimental data. Remodeling , which appears early after the onset of AF, plays an important role in the initiation and maintenance of AF:

★ ★ ★ ★ ★

329 views • 24 slides
Valsartan Lawsuit

Valsartan Lawsuit

In a matter of mere months, the previously little-known pharmaceutical ingredient valsartan has gone from relative obscurity to being at the center of multiple drug recalls and at least one potential class-action lawsuit. https://thelawfirm.com/valsartan-recall-lawsuit/

★ ★ ★ ★ ★

127 views • 10 slides
KYOTO

KYOTO

KYOTO. BP at follow-up: 133/76 mm Hg in both groups Composite CV events: 5.5% with valsartan vs. 10.2% with usual therapy Stroke/TIA: 1.5% vs. 3% Angina: 1.5% vs. 2.9% (p = 0.01) New-onset DM: 5.2% vs. 7.7% (p = 0.028).

★ ★ ★ ★ ★

186 views • 1 slides

View Valsartan PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Valsartan PowerPoint presentations. You can view or download Valsartan presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.